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Figure 1 The effect of varying the peptide-to-heparin ratio in the affinity-based delivery system on growth factor release over a 14-
day time course. (A) Release profile of NT-3 from the delivery system. (B) Release profile of PDGF from the delivery system. (C) Release
profile of Shh from the delivery system. #Pb0.05 versus all other groups. ⁎Pb0.05 versus no delivery system. Error bars indicate
standard deviation.
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Figure 2 The effects of the affinity-based delivery system on ESNPC differentiation and survival inside fibrin scaffolds. (A)
Quantitative analysis of the effects of the different delivery system components on ESNPC differentiation inside fibrin scaffolds. (B)
Quantitative analysis of the effects of the different delivery system components on ESNPC viability inside fibrin scaffolds. ⁎Pb0.05
compared to 14-day control cultures in unmodified fibrin with no growth factors present in the medium. Error bars indicate standard
deviation.
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Figure 3 The effects of controlled growth factor delivery on ESNPC differentiation inside fibrin scaffolds. (A) The effects of controlled release of
various NT-3 doses on ESNPC differentiation. (B) The effects of controlled release of various PDGF doses on ESNPC differentiation. (C) The effects of
controlled release of various Shh doses on ESNPC differentiation. Markers examined included SSEA-1 (undifferentiated ES cells), nestin (neural
progenitors), Tuj1 (early neurons),O4 (oligodendrocytes), andGFAP (astrocytes). ⁎Pb0.05 versus cultures inunmodified fibrinwithnogrowth factors
present in the medium. #Pb0.05 compared to optimal dose with no delivery system present. Error bars indicate standard deviation.
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Figure 4 The effects of controlled delivery of growth factor combinations on ESNPC differentiation and survival inside fibrin
scaffolds. (A) Quantitative analysis of the effects of the various growth factor combinations on ESNPC differentiation after 14 days of
culture. Markers examined included SSEA-1 (undifferentiated ES cells), nestin (neural progenitors), Tuj1 (early neurons), O4
(oligodendrocytes), and GFAP (astrocytes). (B) Real-time RT-PCR analysis to confirm FACS results after 7 days of culture inside scaffolds.
Markers examined included Sox2 (neural progenitors), microtubule-associated protein-2 (Map2; early neurons), platelet-derived
growth factor α receptor (PDGFαR; early oligodendrocytes), and vimentin (astrocytes). (C) Quantitative analysis of the effects of the
various growth factor combinations on ESNPC survival after 14 days of culture. ⁎Pb0.05 versus control cultures in unmodified fibrin with
no growth factors present in the medium. #PN0.05 versus same growth factor combination with no delivery system present. +Pb0.05
versus all other groups. Error bars indicate standard deviation.
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Figure 5 Diagrams showing the affinity-based delivery system and cell culture process. (A) Schematic of the affinity-based delivery system. The bidomain peptide becomes covalently
cross-linked into the fibrin scaffold during polymerization. This peptide contains a heparin-binding domain, allowing heparin to be noncovalently retained inside the scaffold. The
heparin in turn noncovalently binds the growth factor, causing it to remain in the scaffold. (B) Schematic of the process for producing embryoid bodies, followed by seeding and culture
inside the fibrin scaffolds.
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